RVL Pharmaceuticals plc: Nasdaq/NYSE listing notice — RVL Pharma receives Nasdaq deficiency notice for bid price below $1.00

RVL Pharmaceuticals plc

Received Nasdaq deficiency letter on June 2, 2023 for bid price < $1.00 for 30 consecutive business days.
Has 180 days, until Nov 29, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.
May qualify for additional 180-day period by transferring to Nasdaq Capital Market if not cured by Nov 29.
Company may consider a reverse share split to boost share price, subject to board and shareholder approval.
No immediate impact on listing; delisting possible if not cured within compliance periods.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

RVL Pharmaceuticals plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

June 2, 2023, RVL Pharmaceuticals plc (the “Company”) received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s ordinary shares, $0.01 nominal value per share (the “Ordinary Shares”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The deficiency letter has no immediate effect on the list

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-067651

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.